US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Telefónica Q1 2026 Earnings Beat Expectations as Debt Declines and Cash Flow Improves 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
HEIDELBERG, Germany, Sept. 22, 2016 -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Thursday, September 29, 2016 at 1:30 p.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the “Events” section on the “Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
